Skip to main content

Krishnan Suma's Form 4 filing

Krystal Biotech, Inc. (KRYS) · filed Jun 2, 2023

Accession no.
0001298711-23-000015
Filed
Jun 2, 2023
Trade date
May 31, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions. Open-market sales total $5.81M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Krishnan SumaCIK 0001298711Director, Officer (President, R&D), 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 31, 2023Common StockSSaleDisposed−20,143$115.98F1−$2,336,185.141,629,063DirectDuplicate filing
May 31, 2023Common StockSSaleDisposed−4,557$116.86F2−$532,531.021,624,506DirectDuplicate filing
May 31, 2023Common StockSSaleDisposed−300$117.57F3−$35,2711,624,206DirectDuplicate filing
May 31, 2023Common StockSSaleDisposed−18,884$116.00F1−$2,190,5441,690,454IndirectDuplicate filing
May 31, 2023Common StockSSaleDisposed−5,716$116.95F6−$668,486.21,684,738IndirectDuplicate filing
May 31, 2023Common StockSSaleDisposed−400$117.61F7−$47,0441,684,338IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The transaction was executed in multiple trades ranging from $115.5200 to $116.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 2 transactions in Table I.

F2

The transaction was executed in multiple trades ranging from $116.5200 to $117.5100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F3

The transaction was executed in multiple trades ranging from $117.5500 to $117.6000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F6

The transaction was executed in multiple trades ranging from $116.5200 to $117.5000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F7

The transaction was executed in multiple trades ranging from $117.5500 to $117.7200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)